Phospho-eIF4G (Ser1108) Antibody [G15K10]

Catalog No.: F4969

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:1000
    Application
    WB, IHC
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    175 kDa

    Datasheet & SDS

    生物学的記述

    Specificity
    Phospho-eIF4G (Ser1108) Antibody [G15K10] detects endogenous levels of total eIF4G protein only when it is phosphorylated at Ser1108.
    Clone
    G15K10
    Synonym(s)
    Eukaryotic translation initiation factor 4 gamma 1, eIF-4-gamma 1; eIF-4G 1; eIF-4G1, p220, EIF4G1, EIF4F, EIF4G, EIF4GI
    Background
    Phospho‑eIF4G (Ser1108) corresponds to a serum‑regulated, mTOR‑sensitive phosphorylation state of the eukaryotic initiation factor 4G scaffold, which functions within the eIF4F complex to coordinate cap recognition, RNA helicase activity, and recruitment of mRNA to ribosomes, and which integrates growth factor and nutrient signaling into selective control of translation initiation. The eIF4G1 protein contains multiple modular regions that bind eIF4E at the mRNA cap, eIF4A helicase, eIF3 and the 40S ribosomal subunit, and regulatory factors such as 4E‑BPs; its C‑terminal region harbors several serum‑stimulated phosphorylation sites, including Ser1108, that respond to upstream kinase cascades. Phosphorylation at Ser1108 increases after activation of the PI3K–mTOR axis by ligands such as insulin‑like growth factor 1 and is blocked by the PI3K inhibitor LY294002 and by the mTOR/FRAP inhibitor rapamycin, placing this site under direct control of canonical growth and nutrient‑sensing pathways that also regulate p70S6K and 4E‑BP phosphorylation. Ser1108 phosphorylation associates with enhanced eIF4E–eIF4G interaction and activation of cap‑dependent translation, and the degree of phosphorylation at this site correlates with the assembly of active eIF4F complexes and with the translational status of growth‑related mRNAs that rely on efficient cap recognition and 5′‑UTR unwinding. MNK2, a MAPK‑interacting kinase activated by ERK and p38 MAPK, limits eIF4G Ser1108 phosphorylation through a negative regulatory pathway that impacts mTOR signaling: depletion of MNK2 increases Ser1108 phosphorylation and maintains this modification under conditions of rapamycin treatment, starvation, or muscle atrophy, whereas overexpression of MNK2 decreases Ser1108 phosphorylation and reduces p70S6K activation. This relationship defines MNK2 as a brake on mTOR‑dependent activation of eIF4G, establishing phospho‑eIF4G (Ser1108) as a convergence point between MAPK–MNK2 and PI3K–mTOR pathways in the fine‑tuning of translational capacity in skeletal muscle and other insulin‑responsive tissues. The same C‑terminal segment that contains Ser1108 also integrates additional regulatory phosphorylations, generating a combinatorial modification pattern that modulates eIF4A and eIF4B binding, eIF4F stability, and the efficiency of recruiting structured or weakly translated mRNAs, which links phospho‑eIF4G (Ser1108) to broader remodeling of initiation complex composition under anabolic conditions.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください